Beta-Arrestin 1 Mediates Liver Thyrotropin Regulation of Cholesterol Conversion Metabolism via the Akt-Dependent Pathway

International Journal of Endocrinology
Shaona NiuTao Bo

Abstract

After activation, G protein-coupled receptors (GPCRs) are desensitized by β-arrestins (ARRBs). Moreover, ARRBs can initiate a second wave of signaling independent of G proteins. Thyroid-stimulating hormone receptor (TSHR) is one of the GPCR members. In our previous study, TSHR was identified in the liver; the major role of TSHR in cholesterol metabolism was illustrated, as TSH could regulate hepatic cholesterol metabolism via cAMP/PKA/CREB/HMGCR and SREBP2/HNF4α/CYP7A1 pathways. It has been reported that ARRB2 predominates over ARRB1 in TSHR internalization. However, the significance of ARRBs in TSH-initiated cholesterol metabolism has not been illustrated. In our study, the effects of ARRBs on TSH-regulated cholesterol metabolism are investigated. ARRB1/2 was genetically inactivated in C57BL/6 mice and HepG2 cell line, respectively. Cholesterol levels in arrestin-knockout mice and arrestin-knockdown cells were measured. Molecules participating in cholesterol metabolism were analyzed. It turned out that deficiencies in ARRB1 led to decreased cholesterol levels and decreased TSH-stimulated AKT phosphorylation. Subsequently, the inhibitory effect on CYP7A1 by SREBP2 was reduced due to lowered mature SREBP2 level. Other than the f...Continue Reading

References

Jun 1, 1994·Journal of Endocrinological Investigation·M MengistuK D Burman
May 5, 1995·The Journal of Biological Chemistry·T EndoT Onaya
Nov 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·R Paschke, V Geenen
Feb 13, 2001·Endocrinology·P CrisantiB Saunier
Sep 5, 2002·Nature Reviews. Molecular Cell Biology·Kristen L PierceRobert J Lefkowitz
Oct 26, 2002·Science·Stephen J PerryRobert J Lefkowitz
Oct 31, 2002·Nature Reviews. Drug Discovery·Philip Ma, Rodney Zemmel
Oct 22, 2003·Cell·Etsuko AbeMone Zaidi
Jul 3, 2004·Endocrinology·Nadir R Farid, Mariusz W Szkudlinski
Apr 23, 2005·Science·Robert J Lefkowitz, Sudha K Shenoy
Jun 16, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Silvana BalzanGiorgio Iervasi
Jan 15, 2008·Cell·Jean-Martin BeaulieuMarc G Caron
Sep 3, 2008·Cell Metabolism·Thomas PorstmannAlmut Schulze
Feb 4, 2009·Journal of Cellular and Molecular Medicine·Wei ZhangJia-jun Zhao
Sep 29, 2011·Annual Review of Pharmacology and Toxicology·Eric ReiterRobert J Lefkowitz
Oct 19, 2011·Biochimica Et Biophysica Acta·Winnie LuuAndrew J Brown
Apr 24, 2012·Journal of Lipid Research·Mary E MansonThomas J Kelley
Jun 13, 2012·Proceedings of the National Academy of Sciences of the United States of America·Hakryul JoHongbo R Luo
Nov 20, 2015·The Journal of Biological Chemistry·Deling YinGene LeSage

❮ Previous
Next ❯

Methods Mentioned

BETA
gene-knockdown
PCR

Software Mentioned

SPSS
Origin
ImageJ
Adobe Illustrator

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.